# Enovis Corporation (CFX)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Price:** $22.68 (-1.56%)

> Enovis Corporation is a medical technology company focused on developing and manufacturing innovative orthopedic care and rehabilitation solutions. The company operates primarily through two business segments: Prevention & Recovery, which encompasses bracing, supports, and other therapies designed to prevent injury and enhance patient recovery, and Reconstructive, which provides products for joint replacement and surgical interventions aimed at restoring patient mobility. Enovis has evolved from its origins as Colfax Corporation, previously a diversified industrial manufacturing firm, to a dedicated medtech enterprise following significant acquisitions and strategic divestitures, most notably the purchase of DJO for orthopedic platforms and the spinoff of its fabrication technology segment as ESAB Corporation. 

Leveraging a heritage of operational excellence and continuous improvement—principles rooted in the company’s founding by the Rales brothers—Enovis is committed to driving better clinical outcomes and transforming workflows in healthcare settings. It serves hospitals, clinics, and healthcare providers worldwide, contributing to advancements in patient care through innovations that improve mobility and quality of life. Today, Enovis is recognized for its strong focus on growth, industry leadership in orthopedics, and its vital role in the broader health technology sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2021 | $3.85B | $1.61B | $284M | $76M | — |
| 2020 | $3.07B | $1.29B | $201M | $46M | $0.93 |
| 2019 | $3.33B | $1.40B | $269M | -$517M | $-11.67 |
| 2018 | $3.67B | $1.13B | $315M | $154M | $3.48 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2021 | $3.09B | $3.42B | $73M | $719M | $2.22B |
| 2020 | $2.10B | $3.39B | $65M | $97M | $2.34B |
| 2019 | $2.27B | $3.48B | -$4M | $110M | $2.42B |
| 2018 | $2.72B | $2.72B | $212M | $245M | $1.19B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2021 | $340M | -$97M | $252M |
| 2020 | $302M | -$105M | $187M |
| 2019 | -$381M | -$118M | $6M |
| 2018 | $226M | -$35M | $157M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CFX)